

Recent Posts
- Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board
- Kinnate Biopharma Closes $98 Million Series C Financing
- Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer
- Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year
- Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer
Recent Comments